ALiEM - Pharm Pearls

FEBRUARY 28, 2024

This blog post provides an update to our 2018 blog articles to reflect these changes. Accessed February 20, 2024. February 2024. Accessed February 20, 2024. Updated February 2024. Brief Description for: Article Title. Accessed February 20, 2024. Accessed February 20, 2024. Article Title.

130

130

Fuld & Company Blog

AUGUST 28, 2024

Insights at your fingertips Fuld’s US M&A dashboard is a quick yet comprehensive update on the US M&A landscape for H1 2024. What’s inside H1 2024 activity overview: A summary of the major shifts in M&A activity U.S.

52

52

European Pharmaceutical Review

MARCH 1, 2024

This Issue was brought to you in partnership with Fujifilm Irvine Scientific: The post <em>European Pharmaceutical Review </em> Issue 1 2024 appeared first on European Pharmaceutical Review.

64

64

Drug Channels

JANUARY 23, 2024

In a previous article , I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). As you will see below, the largest PSAOs have effectively abandoned PDP’s preferred networks in 2024. Look out below! All rights reserved.

Independent Pharmacies 73

Independent Pharmacies 73

The Thyroid Pharmacist

DECEMBER 29, 2023

My books, articles, supplements, and documentary were in the world for all to find and discover, so I cut back from media and publicity efforts for a few years while I enjoyed mama life. I also released a brand new program focused on gut health, as well as some more helpful articles this year. I am hoping to feel more settled in 2024.

Adverse Reactions 63

Adverse Reactions Immunization Immunity Diabetes 63

Digital Pharmacist

AUGUST 21, 2023

As we gear up for the upcoming flu season of 2023-2024, it’s important to reflect on the lessons of the previous year , and understand how the coming year may look different. 2023 Flu Vaccination Changes As we look at the 2023-2024 flu season, what’s new for this year? According to the CDC, in the 2023-2024 season, the U.S.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Digital Pharmacist

SEPTEMBER 20, 2023

The Medicare Open Enrollment period for 2024 is quickly approaching – this is a critical time for both your patients and your pharmacy. Below is a breakdown of what you need to be aware of when assisting patients with 2024 open enrollments, as well as a few tips on how your pharmacy can prepare for this busy time at the pharmacy.

Independent Pharmacies 105

Independent Pharmacies Nursing Homes Immunity Immunization 105

Fuld & Company Blog

JANUARY 17, 2024

To kick off the New Year, I’d like to share with you some recent client success stories, as well as new ideas for driving revenue and increasing your competitive edge in 2024. In the first article, we share how Fuld recently helped a Private Equity firm increase revenues by 130% by identifying 300 targets in a niche industry.

52

52

Drug Channels

APRIL 29, 2024

on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens' unexpected specialty pharmacy strength A video deconstruction of my infamous Drug Channels article on GoodRx Plus, a cartoonist illustrates my recent keynote on the battle for oncology margin. All rights reserved.

Specialty Pharmacies 93

Specialty Pharmacies Biosimilars 93

Drug Channels

OCTOBER 24, 2023

Open enrollment is under way for the 2024 Medicare Part D plans. For 2024: 94% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. Below, I provide historical data on preferred networks’ growth and update the seven top companies’ 2024 offerings.

Independent Pharmacies 52

Independent Pharmacies 52

ALiEM - Pharm Pearls

MAY 6, 2024

Launching the 2nd edition of Bridge to EM (2024) We are thrilled to announce that we launching the second edition of the curriculum. We also include a broader representation of foundational learning content such as the interpretation of diagnostic imaging as well as professional competency skills (e.g., communication, efficiency).

Communication 189

Communication 189

Pharma Mirror

JANUARY 19, 2024

As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside an abundance of exciting opportunities. The pharmaceutical and contract outsourcing space has shifted, with new trends emerging that will shape the future of this rapidly changing industry.

Vaccines 52

Vaccines 52

Drug Channels

JULY 30, 2024

Go for a swim to cool off and then enjoy this refreshing selection of articles chosen by Drug Channels para tu. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Did the FTC’s compelling interim report prove its case? Attendance will be highly limited, so apply now. All rights reserved.

Biosimilars 40

Biosimilars Hospitals 40

European Pharmaceutical Review

JUNE 27, 2024

In a recent EPR article , investigator on the FRESCO-2 trial, Dr Sebastian Stintzing, highlighted that “with the good toxicity profile of fruqintinib [and] the easy oral administration [in the future we could] see…combinations of fruquintinib, plus either chemotherapeutic substances, target treatment options [or] immunoncology”.

Chemotherapy 64

Chemotherapy 64

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist discusses something cool and something lame with 5 antibiotics. BCPS, BCIDP Article Posted October 2024, First Released in the August 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D.,

52

52

PharmaTech

MAY 12, 2024

This article considers technical and commercial best practices that drug developers may enact so that they, their suppliers and media manufacturers, and in turn, their cell culture media remain on the most efficient path to market. The importance of successfully scaling up cell culture media cannot be overstated.

Drug Development 52

Drug Development 52

Med Ed 101

SEPTEMBER 18, 2024

In this article, we will highlight some of the differences and similarities between Neffy and Epipen. Neffy was approved for patients who weigh over 30 kg or more by the FDA in August of 2024. […] The post Neffy Versus EpiPen – Clinical Comparison appeared first on Med Ed 101.

52

52

Drug Channels

AUGUST 13, 2024

Consider this article to be an opportunity for some fact-based analysis to replace your schadenfreude. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Drug Channels has been tracking retail pharmacies’ economic and business challenges —and Rite Aid’s troubles—for many years.

73

73

Drug Channels

OCTOBER 3, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The article below highlights an underappreciated consequence of the Inflation Reduction Act’s inflation rebates for Medicare Part B drugs. All rights reserved.

Documentation 52

Documentation 52

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist discusses 5 neat things from the world of antimicrobials – let’s get nerdy! BCPS, BCIDP Article Posted October 2024, First Released in the September 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D., Read more here ([link].

52

52

FDA Law Blog: Biosimilars

OCTOBER 16, 2023

Gonzalez — The Wall Street Journal (WSJ) recently published a series of articles as part of its special report “What’s Ahead for Artificial Intelligence.” Three of these articles focus on medical applications of Artificial Intelligence and Machine Learning (AI/ML) and explore FDA’s role in regulating such products.

Documentation 119

Documentation 119

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist with 20+ years of experience in the profession discusses 5 quick things to know about drug shortages. BCPS, BCIDP Article Posted October 2024, First Released in the July 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D.,

Communication 52

Communication 52

European Pharmaceutical Review

OCTOBER 23, 2024

Donanemab was approved by the US Food and Drug Administration (FDA) as Kisunla (donanemab-azbt) in July 2024. This was followed by regulatory approval in Japan in September 2024. .” Results from the TRAILBLAZER-ALZ 2 study were published in the Journal of the American Medical Association (JAMA) in July 2023.

Hospitals 52

Hospitals Drug Development 52

STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 In 2024, as in 2023, the industry’s fate seems inextricable from interest rates. If you’ve made it to the end of this article, you might be interested in joining this  secret list for an upcoming biotech newsletter.

Drug Pricing 318

Drug Pricing Vaccines Communication Drug Development 318

PharmaTech

JANUARY 1, 2024

This article considers technical and commercial best practices that drug developers may enact so that they, their suppliers and media manufacturers, and in turn, their cell culture media remain on the most efficient path to market. The importance of successfully scaling up cell culture media cannot be overstated.

Drug Development 40

Drug Development 40

European Pharmaceutical Review

AUGUST 3, 2023

EPC’s new Cannabis flower monograph The new monograph Cannabis flower (Cannabis flower, monograph 3028) will be available next year in January 2024 with publication of the supplement 11.5. The monograph will enter into force several months later, in July 2024. 1 July 2024).

Compounding 98

Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Safe Biologics

AUGUST 27, 2024

A 2024 survey of 270 U.S. Read the article in GaBI Journal here. Data has shown, however, that these policies are strongly opposed by physicians who prescribe biologics. physicians shows the importance of maintaining the robust data requirements undergirding the interchangeable designation. policy here.

Biosimilars 100

Biosimilars 100

European Pharmaceutical Review

OCTOBER 24, 2024

The biologic treatment was granted approval as Kisunla (donanemab-azbt) in the US by the Food and Drug Administration (FDA) in July 2024. In August 2024, Eisai/Biogen’s anti-Aβ mAb Leqembi (lecanemab) became the first [disease-modifying therapy] to be approved for [Alzheimer’s] in the UK”.

Drug Development 52

Drug Development 52

Fuld & Company Blog

FEBRUARY 12, 2024

Azerbaijan is set to host the 2024 United Nations Climate Change Conference (COP29) in November. This is a summary of an article written by Rauf Mammadov, Senior Manager at Fuld, for the Middle East Institute. You can read the full article here. The post Azerbaijan and COP29: An opportunity or a challenge?

52

52

Drug Channels

DECEMBER 13, 2023

This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. Click here to see the original post from September 2023. Time for our annual update on the channels for provider-administered drugs.

Specialty Pharmacies 93

Specialty Pharmacies Hospitals 93

European Pharmaceutical Review

JANUARY 5, 2024

In EPR’s article last month which discussed predictions for the biopharma industry in 2024 , Subin Baral, EY Global Deals Leader, Life Sciences stated: “Given the unmet need, we expect oncology to continue to dominate dealmaking in 2024.”

115

115

Safe Biologics

JANUARY 12, 2024

CMS accepted public comments on the Proposed Rule until January 5, 2024. Read the full JD Supra article here. UPCOMING EVENTS WHO 78th INN Consultation Geneva, Switzerland – March 19, 2024 ASCO Annual Meeting Chicago, IL – May 31-June 4, 2024 DIA Global Annual Meeting San Diego, CA – June 16-20, 2024

Biosimilars 130

Biosimilars Drug Pricing 130

Big Molecule Watch

OCTOBER 3, 2024

Express Scripts”), one of the largest pharmacy benefit managers (PBMs) in the United States, brought suit against the Federal Trade Commission (“FTC”) over its July 2024 interim report on the PBM industry. On September 17, Express Scripts, Inc. Constitution; (3) violation of the Administrative Procedure Act (“APA”), 5 U.S.C. § Constitution.

Independent Pharmacies 62

Independent Pharmacies 62

Quality Matters

SEPTEMBER 9, 2024

billion in 2024 to over 32 billion in 2030. By engaging in roundtable discussions, drafting stimuli articles, and developing work plans with HQS Expert Committees, USP is setting high-quality standards, covering aspects such as labeling, version control, classification, health equity, and accessibility.

Labelling 52

Labelling Diabetes 52

Big Molecule Watch

FEBRUARY 20, 2024

DMFs are submissions to the FDA “used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products.” The final rule goes into effect on March 13, 2024.

Packaging 57

Packaging 57

Big Molecule Watch

MAY 1, 2024

On April 22, 2024, the PTAB issued final written decisions in IPR2023-00070 and IPR2023-00074 , filed by Bluebird Bio on two patents related to recombinant lentiviral vectors — U.S. The PTAB also ruled that additional references, including an article authored by an inventor, did not anticipate or render obvious the challenged claims.

67

67

FDA Law Blog: Biosimilars

NOVEMBER 9, 2023

Pursuant to FSMA, FDA amended the requirements for prior notice of imported food, to include a requirement to report the name of any country to which the article has been refused entry. The proposed rule also establishes a timeframe by which food articles subject to refusals or holds must become compliant.

52

52